ATLANTA, April 19 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. , a biopharmaceutical company dedicated to the development of innovative gene transfer therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease, announced today the promotion of Todd Stallings to Vice President - Clinical Operations. He will report directly to Richard Otto, President and Chief Executive Officer.
“Todd is a dedicated member of our management team and has been leading our clinical operations department for some time,” said Richard Otto. “Todd has taken on increasing responsibilities during his time at Corautus and has performed at an outstanding level in all areas. As Vice President - Clinical Operations, Todd will play an important role in guiding and managing the expansion of our clinical development programs.”
Mr. Stallings joined Corautus in August 2004 as the clinical trial manager for cardiovascular research and his professional career also includes clinical research experience with phase I-IV trials covering a broad range of therapeutic indications. Mr. Stallings earned his BS at Auburn University, and his MPH in Epidemiology at the University of Alabama at Birmingham.
About Corautus Genetics
Corautus Genetics Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative gene therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease. Corautus is focusing its efforts and resources on the development of gene therapy products using a growth factor known as Vascular Endothelial Growth Factor-2, or VEGF-2, gene to promote therapeutic angiogenesis in ischemic muscle. Corautus has a strategic alliance with Boston Scientific Corporation to develop, commercialize and distribute the VEGF-2 gene therapy products. For more information, please visit www.corautus.com.
Company Contact: Michael K. Steele (404) 526-6212 msteele@corautus.com Investor Relations Contacts: Lippert/Heilshorn & Associates Kim Sutton Golodetz Kgolodetz@lhai.com Anne Marie Fields Afields@lhai.com 212-838-3777
Corautus Genetics Inc.
CONTACT: Michael K. Steele of Corautus Genetics Inc., +1-404-526-6212, ormsteele@corautus.com; or Investor Relations, Kim Sutton Golodetz,Kgolodetz@lhai.com, or Anne Marie Fields, Afields@lhai.com, ofLippert-Heilshorn & Associates, +1-212-838-3777
Web site: http://www.corautus.com/
